Pivotal Therapeutics VASCAZENÂ®-REVEAL trial meets primary and secondary endpoints - VASCAZENÂ® shows 121% correction of an Omega-3 deficiency (p< 0.0001) with a concomittant 48% reduction in triglycerides (p<0.0005)